Eureka Therapeutics Stock
Eureka Therapeutics is a biotechnology company focuses on an immunotherapies for the treatment of cancer.
Sign up today and learn more about Eureka Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Eureka Therapeutics Stock
Eureka Therapeutics pursues innovations that will change the world. We develop technologies that advance the field of antibody therapeutics by increasing the efficacy and specificity of antibody drugs, and the expression level of antibody cell lines. Eureka also provides a wide array of contract research services available to other companies. These services center around cell line development and antibody production or purification.
Funding History
| January 2007 | $1K |
|---|---|
| August 2007 | $1.2M |
| November 2008 | $1.7M |
| September 2014 | $21.0M |
| January 2018 | $60.0M |
Management
Research Scientist
Shon Green
Founder, CEO
Cheng Liu
Press
bioworld - Mar, 17 2023
Eureka Therapeutics licenses antibody targeting mesothelin from NCIbiospace - Oct, 18 2022
Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastomafiercebiotech - Jul, 14 2021
ACB hires Liu from Eureka Therapeutics to lead push into cliniczpr - Jul, 7 2021
Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myelomabioworld - Oct, 7 2020
Eureka Therapeutics begins phase I/II trial of T-cell therapy in HCCendpts - Mar, 18 2020
Rick Klausner's Lyell partners, helps fund Eureka's work on cell therapies; Blueprint bounces higher on PhIIendpts - Mar, 18 2020
Rick Klausner's Lyell partners, helps fund Eureka's work on cell therapies; Blueprint bounces higher on PhIIbusinesswire - Feb, 19 2020
Eureka Therapeutics to Present at the CAR-TCR Summit Europebioportfolio - Aug, 6 2019
Eureka Therapeutics Starts US Trial of Liver Cancer T-Cell Therapybusinesswire - Jul, 20 2018
Eureka Therapeutics Announces that Boehringer Ingelheim is Exercising an Option to License Novel TCR Mimic (TCRm) Antibodiesbusinesswire - Jun, 10 2018
Eureka Therapeutics Announces Positive Preliminary Results of ET190L1-ARTEMISTM T-cell China Proof-of-Concept Human Clinical Study in Relapsed and Refractory (r/r) B-cell Lymphoma at ASCO Annual Meetingprnewswire - May, 1 2017
Global CAR T Cell Therapy Market & Clinical Trials Insight 2022: Pipeline Analysis by Company, Indication & Phase - Research and Marketsprnewswire - Jan, 8 2016
Eureka Therapeutics Announces Exclusive License Agreement between Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Use of a Novel, Fully-Human MUC16 Binder in CAR T Cell Immunotherapybusinesswire - Oct, 22 2015
T-Cell Immunotherapy Market to Be Worth USD 30 Billion by 2030, Predicts Roots Analysisbusinesswire - Sep, 29 2015
Research and Markets: Engineered TCR and CAR Immunotherapeutics Analysis Report 2015xconomy - May, 22 2015
West Coast Biotech Roundup: Ebola, Immunotherapy, Avalon & More | XconomyEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
